Brokerages predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post ($0.22) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.28). Ironwood Pharmaceuticals posted earnings of ($0.12) per share during the same quarter last year, which would indicate a negative year over year growth rate of 83.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, February 20th.

On average, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.19) to ($1.05). For the next year, analysts forecast that the company will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.80) to ($0.32). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The company had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. During the same period in the prior year, the firm posted ($0.18) EPS. The company’s quarterly revenue was up 31.3% on a year-over-year basis.

A number of research analysts have weighed in on IRWD shares. Morgan Stanley reaffirmed a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Mizuho downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $20.00 to $16.00 in a report on Wednesday. Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. Finally, BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $17.88.

Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) traded down $0.03 during midday trading on Thursday, reaching $15.09. 1,271,082 shares of the company traded hands, compared to its average volume of 1,308,441. Ironwood Pharmaceuticals has a fifty-two week low of $13.43 and a fifty-two week high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.

Large investors have recently modified their holdings of the business. Ameriprise Financial Inc. bought a new position in Ironwood Pharmaceuticals during the second quarter worth about $1,472,000. Oppenheimer Asset Management Inc. boosted its position in Ironwood Pharmaceuticals by 592.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock worth $338,000 after purchasing an additional 15,295 shares during the period. Russell Investments Group Ltd. boosted its position in Ironwood Pharmaceuticals by 281.9% during the second quarter. Russell Investments Group Ltd. now owns 101,676 shares of the biotechnology company’s stock worth $1,920,000 after purchasing an additional 75,055 shares during the period. State of Wisconsin Investment Board boosted its position in Ironwood Pharmaceuticals by 148.4% during the second quarter. State of Wisconsin Investment Board now owns 621,000 shares of the biotechnology company’s stock worth $11,724,000 after purchasing an additional 371,000 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Ironwood Pharmaceuticals by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 104,571 shares of the biotechnology company’s stock worth $1,974,000 after purchasing an additional 3,681 shares during the period.

ILLEGAL ACTIVITY WARNING: “-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2017/12/07/0-22-earnings-per-share-expected-for-ironwood-pharmaceuticals-inc-irwd-this-quarter.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.